Thursday § March 4, 2010
New Dementia Drug in Development Fails Initial Study
Pfizer’s current research on a potential blockbuster anti-Alzheimer drug is currently back to drawing-board status. According to the pharma company
[T]he drug, called Dimebon, had shown virtually no effect after six months in treating the cognitive decline or behavioral problems associated with Alzheimer’s when compared with a placebo.
Apparently, Wall Street has been watching the results of this Phase I study; the verdict is still out on whether Pfizer will continue to fund the research for this agent — designed to work better and longer at inhibiting some of the most distressing symptoms related to the disease. | LINK
Related Posts Within Doctor Pundit:
- Study Highlights Possible ‘Nutritional’ Beverage for Dementia A nationwide clinical trial is underway to determine if a...
- Scientists Find New Avenue in Mechanism of Alzheimer Dementia Development The major focus of research into the biochemical causes and...
- Study: First Available Mega-Combination Cardiac Drug in Development Sometimes the fastest way from an NDA to market is...
Doctor Pundit is now on the proprietary Amazon e-reader, the Kindle. Do you own one? Consider getting each and every post delivered wirelessly. Don't miss a single health policy moment. 